BioSpace News Archive

Biotech Beach

Volition Issues Business Review 2022

VolitionRx Limited, a multi-national epigenetics company, has issued a Business Review of 2022, outlining its key highlights as the organization transitions from a company solely focused on research and development to one with commercial operations.

January 8, 2023
·
4 min read
Business

Exact Sciences Announces Preliminary Fourth Quarter 2022 Results

Exact Sciences Corp. announced that the company expects to report revenue between $550.7 million and $552.7 million for the fourth quarter ended Dec. 31, 2022.

January 8, 2023
·
10 min read
Business

RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial and Operational Results

RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2022.

January 8, 2023
·
4 min read
Business

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2023

Hologic, Inc. announced preliminary revenue results for its first fiscal quarter ended December 31, 2022.

January 8, 2023
·
12 min read
IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S

IMV Inc., a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, outlined its planned 2023 milestones to advance the clinical development of its lead therapeutic, maveropepimut-S.

January 8, 2023
·
7 min read
Drug Development

Genexine to Present Final Phase 2 Clinical Data on Its Cervical Cancer Program Showing a 35.0% Overall Response Rate and Provide a Corporate Overview During JP Morgan Conference

Genexine announced updated results following the completion of its Phase 2 clinical study using GX-188E, its first-in-class proprietary DNA vaccine, in combination with KEYTRUDA®, MSD’s anti-PD-1 therapy.

January 8, 2023
·
5 min read